GE Healthcare

Named as a key player in 1,254 of our reports, across 33 regions and countries.

[1] ClinicalTrials.gov, Studies led by GE Healthcare or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Recent reports naming GE Healthcare

Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.

All 1,254 reports

Companies they compete with most

Named as key players in the same markets as GE Healthcare (number of shared markets).

Public data

Free public data on GE Healthcare

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Stock listing
NYSE: GE
Type
Other

Source: SEC EDGAR, Company filings, CIK 40545. Retrieved 13 Nov 2026.

US device clearances

100 510(k) clearances and PMA approvals since 2015

Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Includes GE Healthcare Finland Oy, Ge Healthcare Japan Corporation. Retrieved 13 Nov 2026.

See them on openFDA (opens in a new tab)

US recalls

457 recalls since 2015 (457 for devices)

Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Includes GE Healthcare Finland Oy, Ge Healthcare Japan Corporation. Retrieved 13 Nov 2026.

See them on openFDA (opens in a new tab)

Trials over time

Studies GE Healthcare leads, by the year they started and their phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with GE Healthcare or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Also active in

Markets we cover where free public records show GE Healthcare: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Search all reports for GE Healthcare All companies